Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.67 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALB | P02768 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14546727 | 1.00 | TK1 (0.67) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL8428685 | 1.00 | TK1 (0.67) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL2230026 | 1.00 | TK1 (0.67) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL3037394 | 0.94 | TK1 (0.65) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL11910917 | 0.94 | TK1 (0.65) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL29391024 | 0.93 | RNASE1 (0.61) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL29402962 | 0.92 | TK1 (0.67) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL29355784 | 0.92 | TK1 (0.67) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL19223589 | 0.92 | TK1 (0.63) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL19146444 | 0.92 | TK1 (0.63) | TK1RNASE1LMNATSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | claimed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | claimed |
| CN-119677852-A | Compositions and methods for inhibiting expression of signal-regulating protein alpha (SIRPalpha) genes | 麻省理工学院 | 2025-03-21 | — | — | CN | claimed |
| WO-2025044868-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AND USE THEREOF IN INHIBITING EXPRESSION OF ANGIOTENSINOGEN | 苏州炫景生物科技有限公司 | 2025-03-06 | — | — | WO | claimed |
| CN-119530218-A | Double-stranded oligonucleotides and their use in inhibiting expression of angiotensinogen | 苏州炫景生物科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| WO-2025039996-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE INHIBITING LPA GENE EXPRESSION AND USE THEREOF | 苏州炫景生物科技有限公司 | 2025-02-27 | — | — | WO | claimed |
| CN-119506275-A | Double-stranded oligonucleotide for inhibiting LPA gene expression and application thereof | 苏州炫景生物科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-118995719-B | Double-stranded oligonucleotide for inhibiting LPA gene expression and application thereof | 北京炫景瑞医药科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119265191-A | Hepatitis B Virus (HBV) dsRNA agent compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-119156448-A | SNCA-targeted siRNA compositions for the treatment of SNCA-related diseases | 阿尔尼拉姆医药品有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-114728018-A | Huntington (HTT) iRNA pharmaceutical compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2021257568-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | WO | claimed |
| WO-2021202902-A1 | ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | claimed |
| WO-2021150969-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-07-29 | — | — | WO | claimed |
| EP-3354733-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | ALNYLAM PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| EP-3354733-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | Alnylam Pharmaceuticals, Inc. (US) | 2018-08-01 | — | — | EP | claimed |
| EP-1501938-B1 | ANALYSIS OF SUBSTRATE UTILIZATION BY ANIMAL OR PLANT CELLS | BIOLOG INC (US) | 2009-10-21 | — | — | EP | claimed |
| US-6727076-B2 | UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES | BIOLOG, INC. | 2004-04-27 | — | — | US | claimed |
| US-20030162164-A1 | Comparative phenotype analysis of cells, including testing of biologically active compounds | BIOLOG, INC. | 2003-08-28 | — | — | US | claimed |
| US-6472201-B1 | GROWING AND TESTING MICROORGANISMS IN A MULTITEST FORMAT WHICH UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES | BIOLOG, INC. | 2002-10-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | TK1 950/4885RNASE1 3/4885LMNA 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.